Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercebiotech.com
FierceBiotech
Get the latest updates from FierceBiotech directly as they happen.
Follow now 338 followers
Latest posts
Last updated about 7 hours ago
United Therapeutics pays $140M for thymic cell therapy startup
about 7 hours ago
United Therapeutics has paid $140 million to buy Thymmune Therapeutics for preclinical...
AstraZeneca pens $1.7B kidney drug discovery pact with go-to Chinese partner CSPC
about 7 hours ago
AstraZeneca has added another piece to its sprawling interface with CSPC Pharmaceutical...
Fosun pays $32M to join Lilly and Novartis in fiercely competitive psoriasis market
1 day ago
A Fosun Pharma subsidiary has paid Junshi Biosciences 215 million yuan ($32...
Roche orchestrates phase 3 KRAS lung cancer win over Amgen, BMS
1 day ago
Roche’s investigational KRAS G12C inhibitor has beaten Amgen’s Lumakras and Bristol Myers...
Insilico keeps partnership sprint apace in $600M biobucks collab with Takeda
2 days ago
Insilico Medicine has signed a deal worth up to $600 million with...
Merck halts ph. 2 Alzheimer’s trial after Neuphoria small molecule underwhelms
2 days ago
Merck & Co. has nixed the phase 2 study of a potential...
Zimmer Biomet buys non-drug pain relief system from Pacira for up to $140M
2 days ago
Pacira BioSciences offloaded its cold-therapy pain relief device to medtech orthopedics specialist...
Biotechs ‘in better position to avoid workforce reductions’ as layoffs continue to ease in Q2’26
2 days ago
A sharp reduction in layoffs continued in the second quarter, extending a...
Ipsen gets the Memo, penning €700M deal to buy rare disease biotech for clinical-stage asset
2 days ago
Ipsen is on a roll this week, scooping up its second biotech...
Backed by top-tier VCs, stealthy biotech bags AlzeCure Alzheimer’s asset in $2.2B deal
2 days ago
QuantumCell has licensed AlzeCure Pharma’s Alzheimer’s disease platform and lead asset for...
Can We Outrun Cancer's Evolution? Why BrYet Is Targeting Cancer-Specific Phenotypes
3 days ago
Genetic instability makes metastatic cancer largely incurable. BrYet aims to work around...
Bain-backed bone specialist Angitia drops lead spinal fusion candidate
3 days ago
Coming on the heels of a $130 million fundraising round just four...